Navigation Links
Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
Date:4/10/2008

- Full Results to be Presented at European Association for the Study of the

Liver Annual Meeting -

SAN FRANCISCO, April 10 /PRNewswire/ -- Antipodean Pharmaceuticals, Inc. announced today that it has completed its Phase 2 study of its lead compound, MitoQ(R) (mitoquinone) in liver disease. The results of the study will be presented at The European Association for the Study of the Liver (EASL) Annual Meeting, being held April 23 - 27 in Milan, Italy.

The poster, titled "Phase II Study of the Mitochondrial Antioxidant Mitoquinone for Hepatitis C," will be presented April 24, 2008. The 28-day study enrolled 30 patients with Hepatitis C virus (HCV), who had not responded to or were unsuitable for interferon or ribavirin treatment, and measured the effect of MitoQ(R) on liver function tests. Edward Gane, M.D., Associate Professor of Medicine, New Zealand Liver Transplant Unit at Auckland City Hospital, served as principal investigator for the study.

About Hepatitis C Virus (HCV)

HCV, a viral infection of the liver, affects over 170 million people worldwide. Approximately 3 million people in the United States have chronic Hepatitis C infections; however, the true prevalence may be underestimated, since newly infected people usually are asymptomatic for many years. HCV infection is the leading cause of cirrhosis, hepatocellular carcinoma, and liver failure. Current treatment strategies focus on achieving a sustained virologic response, but available therapies have poor side-effect profiles and eradicate HCV in only approximately 50% of individuals. New novel therapies for eradicating the HCV virus and slowing the progression of liver scarring are needed. Evidence shows that HCV can directly alter mitochondrial function, leading to increased reactive oxygen species (free-radical) production that can lead to scarring of the liver and cirrhosis.

About MitoQ(R)

MitoQ(R) is a mitochondria-targeted antioxidant that selectively blocks mitochondrial oxidative damage and prevents liver cell apoptosis. MitoQ(R) is based on a novel technology, targeted lipophilic cations that transport and concentrate antioxidants into the mitochondria -- organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold.

About Antipodean

Antipodean is a clinical-stage pharmaceutical company developing targeted molecules that prevent oxidative damage to endothelial, epithelial and liver cells leading to apoptosis and fibrosis. The company has research collaborations with pre-clinical and clinical investigators in Cambridge, UK, Auckland, New Zealand, and several centers in the US to identify and develop lead compounds through to clinical proof-of-principle. Currently the company's lead compounds target liver and skin diseases. Antipodean is located in San Francisco, California. Further information is available at http://www.antipodeanpharma.com


'/>"/>
SOURCE Antipodean Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
2. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
3. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
4. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
6. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
7. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
8. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
9. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
10. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
11. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Potrero Medical, Inc., the developer of the Accuryn™ critical care ... George M. Rapier, III , MD, to its Board of ... is one of the nation,s largest physician owned practice management ... Texas and Florida . ... medicine practice, he has been instrumental to the company,s growth ...
(Date:2/11/2016)... N.C. , Feb. 11, 2016 ... leading provider of custom manufacturing and development services ... expanded sterile fill-finish capabilities and capacity in its ... growth in demand has driven several recent investments. ... 2001 it had one filling line with small-scale ...
(Date:2/11/2016)... ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or 120% of its original funding ... be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers out of South ...
Breaking Medicine Technology:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... experience performing a wide range of cosmetic procedures. Along with performing procedures, the ... efficiency and results of many cosmetic procedures. One of the most common procedures ...
(Date:2/11/2016)... ... February 11, 2016 , ... Image One USA ... new market, and it’s the buildings of Nashville that will benefit. , “I’ve enjoyed ... to relocate to Nashville, there was no question that I would bring my business ...
(Date:2/11/2016)... ... 11, 2016 , ... Hall Integrative Health and Chiropractic, PC ... simultaneous grand openings in March. All seven practices are set to start accepting ... reversing diabetes possible? According to this 2011 CNN article it is possible: ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new ... plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the ... recommendations for rhinoplasty surgeons when addressing this vital area. , The upper lateral ...
(Date:2/11/2016)... NJ (PRWEB) , ... February 11, 2016 , ... ... the call for nominations seeking candidates for the Board of Commissioners. Individuals interested ... passion, skills and experience with diversity of clinical practice settings and across allied ...
Breaking Medicine News(10 mins):